Aurinia Pharmaceuticals Inc
AUPH15.680USD
+0.540+3.57%
Close 11/21, 16:00（ET）Quotes delayed by 15 min
2.07BMarket Cap
26.56P/E TTM
More Details of Aurinia Pharmaceuticals Inc Company
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Aurinia Pharmaceuticals Inc Info
Ticker SymbolAUPH
Company nameAurinia Pharmaceuticals Inc
IPO dateJul 16, 2001
CEOMr. Peter S. Greenleaf
Number of employees130
Security typeOrdinary Share
Fiscal year-endJul 16
Address#140, 14315 - 118 Avenue
CityEDMONTON
Stock exchangeNASDAQ Global Market Consolidated
CountryCanada
Postal codeT5L 4S6
Phone12507442487
Websitehttps://www.auriniapharma.com
Ticker SymbolAUPH
IPO dateJul 16, 2001
CEOMr. Peter S. Greenleaf
Company Executives of Aurinia Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
8.59%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.72%
New Enterprise Associates (NEA)
3.01%
Arrowstreet Capital, Limited Partnership
2.56%
Other
76.16%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
8.59%
ILJIN SNT Co., Ltd.
4.96%
BlackRock Institutional Trust Company, N.A.
4.72%
New Enterprise Associates (NEA)
3.01%
Arrowstreet Capital, Limited Partnership
2.56%
Other
76.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
15.32%
Hedge Fund
15.04%
Investment Advisor
12.87%
Corporation
4.96%
Research Firm
3.21%
Venture Capital
3.03%
Individual Investor
2.49%
Pension Fund
0.78%
Bank and Trust
0.31%
Other
41.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
437
58.52M
44.38%
-12.84M
2025Q2
446
77.42M
58.75%
-1.04M
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
10.03M
7.62%
--
--
Jun 30, 2025
ILJIN SNT Co., Ltd.
6.54M
4.96%
-984.75K
-13.10%
Aug 12, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
4.91%
-1.01M
-13.48%
Jun 30, 2025
New Enterprise Associates (NEA)
3.97M
3.02%
--
--
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
1.08M
0.82%
-564.31K
-34.40%
Jun 30, 2025
State Street Investment Management (US)
2.80M
2.12%
-56.08K
-1.97%
Jun 30, 2025
The Vanguard Group, Inc.
1.69M
1.29%
-250.93K
-12.90%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.58M
1.2%
-157.24K
-9.07%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.24%
Janus Henderson Small Cap Growth Alpha ETF
1.98%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.02%
ALPS Medical Breakthroughs ETF
0.83%
SPDR S&P International Small Cap ETF
0.21%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.18%
Vanguard US Multifactor ETF
0.17%
ProShares Ultra Nasdaq Biotechnology
0.15%
Invesco Nasdaq Biotechnology ETF
0.15%
Avantis US Small Cap Equity ETF
0.13%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.24%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.98%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion1.02%
ALPS Medical Breakthroughs ETF
Proportion0.83%
SPDR S&P International Small Cap ETF
Proportion0.21%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.18%
Vanguard US Multifactor ETF
Proportion0.17%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Invesco Nasdaq Biotechnology ETF
Proportion0.15%
Avantis US Small Cap Equity ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aurinia Pharmaceuticals Inc?
The top five shareholders of Aurinia Pharmaceuticals Inc are:
Tang Capital Management, LLC holds 10.03M shares, accounting for 7.62% of the total shares.
ILJIN SNT Co., Ltd. holds 6.54M shares, accounting for 4.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.46M shares, accounting for 4.91% of the total shares.
New Enterprise Associates (NEA) holds 3.97M shares, accounting for 3.02% of the total shares.
Arrowstreet Capital, Limited Partnership holds 1.08M shares, accounting for 0.82% of the total shares.
Tang Capital Management, LLC holds 10.03M shares, accounting for 7.62% of the total shares.
ILJIN SNT Co., Ltd. holds 6.54M shares, accounting for 4.96% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.46M shares, accounting for 4.91% of the total shares.
New Enterprise Associates (NEA) holds 3.97M shares, accounting for 3.02% of the total shares.
Arrowstreet Capital, Limited Partnership holds 1.08M shares, accounting for 0.82% of the total shares.
What are the top three shareholder types of Aurinia Pharmaceuticals Inc?
The top three shareholder types of Aurinia Pharmaceuticals Inc are:
Tang Capital Management, LLC
ILJIN SNT Co., Ltd.
BlackRock Institutional Trust Company, N.A.
Tang Capital Management, LLC
ILJIN SNT Co., Ltd.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Aurinia Pharmaceuticals Inc (AUPH)?
As of 2025Q3, 437 institutions hold shares of Aurinia Pharmaceuticals Inc, with a combined market value of approximately 58.52M, accounting for 44.38% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.36%.
What is the biggest source of revenue for Aurinia Pharmaceuticals Inc?
In FY2024, the -- business generated the highest revenue for Aurinia Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
